ROCHE HLDGS AG (RHHBY)

32.48
0.28 0.85
OTC
Prev Close 32.20
Open 32.57
Day Low/High 32.37 / 32.61
52 Wk Low/High 26.30 / 32.72
Volume 1.51M
Exchange OTC
Shares Outstanding 702.56B
Market Cap 183.28B
Div & Yield N.A. (N.A)
Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death For People With Advanced Squamous Non-Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that results from the Phase III IMpower131 study showed TECENTRIQ ® (atezolizumab) plus chemotherapy (carboplatin and ABRAXANE ® [albumin-bound paclitaxel;...

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Phase III IMpower130 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Helped People With Metastatic Non-Squamous Non-Small Cell Lung Cancer Live Significantly Longer Compared To Chemotherapy Alone

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower130 study met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS).

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech's HEMLIBRA (emicizumab-kxwh) Reduced Treated Bleeds By 96 Percent Compared To No Prophylaxis In Phase III HAVEN 3 Study In Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today full results from the Phase III HAVEN 3 study evaluating HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in people with hemophilia A...

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Follow-up Phase III Data Showed Genentech's Alecensa Helped People With ALK-Positive Metastatic Non-Small Cell Lung Cancer Live A Median Of Almost Three Years Without Their Disease Worsening Or Death

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced follow-up data from the Phase III ALEX study, showing that as an initial treatment Alecensa ® (alectinib) significantly reduced the risk of disease progression or death...

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ And Avastin Plus Carboplatin And Paclitaxel Helped People With A Specific Type Of Metastatic Lung Cancer Live Significantly Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower150 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Polyarticular Juvenile Idiopathic Arthritis (PJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech To Present New Phase III Data For HEMLIBRA (emicizumab-kxwh) In People With Hemophilia A At The World Federation Of Hemophilia 2018 World Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that Phase III results for HEMLIBRA ® (emicizumab-kxwh) will be presented for the first time during the World Federation of Hemophilia (WFH) 2018 World Congress from May...

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech Provides Update On Phase III Study Of TECENTRIQ (Atezolizumab) And COTELLIC (Cobimetinib) In People With Heavily Pre-Treated Locally Advanced Or Metastatic Colorectal Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMblaze370 study evaluating the combination of TECENTRIQ ® (atezolizumab) and COTELLIC ® (cobimetinib) did not meet its primary endpoint of overall...

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech To Present New Data From Its Industry-Leading Oncology Portfolio At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from early and late-stage clinical studies on more than 19 approved and investigational cancer medicines, will be presented at the 2018 American Society of...

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

FDA Grants Priority Review To Genentech's Cancer Immunotherapy TECENTRIQ (Atezolizumab) For Initial Treatment Of People With A Specific Type Of Metastatic Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

New OCREVUS (Ocrelizumab) Data At AAN Demonstrate Significant Reductions In Disease Activity And Disability Progression In Relapsing Multiple Sclerosis

New OCREVUS (Ocrelizumab) Data At AAN Demonstrate Significant Reductions In Disease Activity And Disability Progression In Relapsing Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS® (ocrelizumab) data were presented at the 70 th American Academy of Neurology (AAN) Annual Meeting from April 21-27 in Los Angeles, California.

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

Biosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day

The pharmaceutical firm will conduct its investor day in New York City on April 11.

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial...

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Shionogi's Single-Dose Flu Drug Gets Japanese Approval

Shionogi's Single-Dose Flu Drug Gets Japanese Approval

The drug likely wouldn't be approved in the U.S. before 2019, however.

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street futures are edging higher amid a "Super Thursday" of corporate earnings that will culminate with Apple's much-anticipated quarterly update and the first official indication on sales of its flagship iPhone X.

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

Roche And Ignyta Reach Definitive Merger Agreement

Roche And Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan ® (rituximab)...

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated...